PARATHYROID HORMONE ANALOGS
Forteo (teriparatide), Tymlos (abaloparatide)

Pre - PA Allowance
None

Prior-Approval Requirements

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

**Forteo and Tymlos**

1. Postmenopausal women with osteoporosis

   **AND ONE** of the following:
   a. History of an osteoporotic low trauma fracture of the spine, hip, proximal humerus, pelvis, or distal forearm
   b. Inadequate response, intolerance or contraindication to oral or injectable bisphosphonate

**Forteo ONLY**

1. Primary or hypogonadal osteoporosis in men

   **AND ONE** of the following:
   a. History of an osteoporotic low trauma fracture of the spine, hip, proximal humerus, pelvis, or distal forearm
   b. Inadequate response, intolerance or contraindication to oral or injectable bisphosphonate

2. Osteoporosis associated with sustained systemic glucocorticoid therapy

   **AND ONE** of the following:
   a. History of an osteoporotic low trauma fracture of the spine, hip, proximal humerus, pelvis, or distal forearm
   b. Inadequate response, intolerance or contraindication to oral or injectable bisphosphonate **AND** the following:
      i. Currently receiving or will be initiating glucocorticoid therapy
PARATHYROID HORMONE ANALOGS
Forteo (teriparatide), Tymlos (abaloparatide)

AND NONE of the following:

a. Risk for osteosarcoma
b. Paget’s disease
c. Unexplained elevations of alkaline phosphatase
d. Prior bone radiation
e. Bone metastases or a history of skeletal malignancies
f. Metabolic bone diseases other than osteoporosis
g. High levels of calcium
h. Patient has used any parathyroid hormone analogs including Forteo (teriparatide) or Tymlos (abaloparatide) cumulatively for longer than 24 months
i. Concurrent therapy with other human parathyroid hormone related peptide analogs (see Appendix 1)
j. Concurrent therapy with another Prior Authorization (PA) medication for osteoporosis (see Appendix 2)

Prior - Approval Limits

<table>
<thead>
<tr>
<th><strong>Forteo</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Quantity</strong></td>
<td>3 multi-dose prefilled pens per 84 days</td>
</tr>
<tr>
<td><strong>Duration</strong></td>
<td>12 months</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Tymlos</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Quantity</strong></td>
<td>3 multi-dose prefilled pens per 90 days</td>
</tr>
<tr>
<td><strong>Duration</strong></td>
<td>12 months</td>
</tr>
</tbody>
</table>

Prior – Approval Renewal Requirements

**Age**
18 years of age or older

**Diagnoses**

Patient must have **ONE** of the following:

**Forteo and Tymlos**

1. Postmenopausal women with osteoporosis

**Forteo ONLY**

1. Primary or hypogonadal osteoporosis in men
PARATHYROID HORMONE ANALOGS

**Forteo** (teriparatide), **Tymlos** (abaloparatide)

2. Osteoporosis associated with sustained systemic glucocorticoid therapy

AND NONE of the following:

a. Risk for osteosarcoma  
b. Paget’s disease  
c. Unexplained elevations of alkaline phosphatase  
d. Prior bone radiation  
e. Bone metastases or a history of skeletal malignancies  
f. Metabolic bone diseases other than osteoporosis  
g. High levels of calcium  
h. Patient has used any parathyroid hormone analogs including Forteo (teriparatide) or Tymlos (abaloparatide) cumulatively for longer than 24 months  
i. Concurrent therapy with other human parathyroid hormone related peptide analogs (see Appendix 1)  
j. Concurrent therapy with another Prior Authorization (PA) medication for osteoporosis (see Appendix 2)

Prior - Approval **Renewal Limits**

**Forteo**

<table>
<thead>
<tr>
<th>Quantity</th>
<th>3 multi-dose prefilled pens per 84 days</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duration</td>
<td>12 months <em>(Only ONE renewal)</em></td>
</tr>
</tbody>
</table>

**Tymlos**

<table>
<thead>
<tr>
<th>Quantity</th>
<th>3 multi-dose prefilled pens per 90 days</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duration</td>
<td>12 months <em>(Only ONE renewal)</em></td>
</tr>
</tbody>
</table>
Appendix 1 - List of human parathyroid hormone related peptide analogs

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Brand Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>abaloparatide</td>
<td>Tymlos</td>
</tr>
<tr>
<td>Teriparatide</td>
<td>Forteo</td>
</tr>
</tbody>
</table>

Appendix 2 - List of PA Osteoporosis Medications

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Brand Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>abaloparatide</td>
<td>Tymlos</td>
</tr>
<tr>
<td>denosumab</td>
<td>Prolia</td>
</tr>
<tr>
<td>romosuzumab-aqqg</td>
<td>Evenity</td>
</tr>
<tr>
<td>Teriparatide</td>
<td>Forteo</td>
</tr>
</tbody>
</table>